share_log

10-Q: Q1 2024 Earnings Report

10-Q: Q1 2024 Earnings Report

10-Q:2024財年一季報
美股SEC公告 ·  06/28 16:58

Moomoo AI 已提取核心訊息

FOXO Technologies Inc. reported financial results for the quarter ended March 31, 2024, with total revenue at $7, a decrease from $13 in the same period the previous year. The company experienced a net loss of $1,504, an improvement from a net loss of $7,639 in the prior year's quarter. The reduced net loss was primarily due to a decrease in operating expenses, which fell from $7,405 to $1,186, driven by lower research and development costs, management contingent share plan expenses, and selling, general and administrative expenses. Non-operating expenses increased slightly due to higher interest expenses. The company also recognized a deemed dividend of $656 related to the extension of certain warrants. FOXO Technologies continues to focus on commercializing epigenetic biomarker technology and has paused sales of...Show More
FOXO Technologies Inc. reported financial results for the quarter ended March 31, 2024, with total revenue at $7, a decrease from $13 in the same period the previous year. The company experienced a net loss of $1,504, an improvement from a net loss of $7,639 in the prior year's quarter. The reduced net loss was primarily due to a decrease in operating expenses, which fell from $7,405 to $1,186, driven by lower research and development costs, management contingent share plan expenses, and selling, general and administrative expenses. Non-operating expenses increased slightly due to higher interest expenses. The company also recognized a deemed dividend of $656 related to the extension of certain warrants. FOXO Technologies continues to focus on commercializing epigenetic biomarker technology and has paused sales of new life insurance products to conserve cash. The company's liquidity position remains a concern, with cash and cash equivalents of $3 as of March 31, 2024, and ongoing efforts to secure additional funding. The company's future plans include pursuing strategic acquisitions, such as the proposed acquisition of Rennova Community Health, Inc., which is expected to provide positive operating cash flows, although there is no assurance of the transaction's completion or success.
FOXO 科技公司報告了截至 2024 年 3 月 31 日的財務業績,總收入爲 7 美元,較去年同期的 13 美元有所下降。該公司淨虧損爲 1,504 美元,較上一年同期的淨虧損 7,639 美元有所改善。減少的淨虧損主要是由於營業費用的下降,從 7,405 美元降至 1,186 美元,這是由於研發成本、管理持續股票計劃支出和銷售、一般和行政支出的降低推動的。非營業性支出由於利息費用增加而略有增加。公司還認定了一項 656 美元的股票期權的視爲股息。FOXO 科技公司繼續專注於商業化表觀遺傳標誌物科技,暫停銷售新的壽險產品以保護現金。公司的流動性地位仍然令人關注,截至 2024 年 3 月 31 日,現金及現金等價物爲 3 美元,並正在努力獲得額外資金支持。公司未來的計劃包括追求戰略收購,例如提議收購 Rennova 社區健康公司,該收購預計將提供正面的營業性現金流,但無法保證交易完成或成功。
FOXO 科技公司報告了截至 2024 年 3 月 31 日的財務業績,總收入爲 7 美元,較去年同期的 13 美元有所下降。該公司淨虧損爲 1,504 美元,較上一年同期的淨虧損 7,639 美元有所改善。減少的淨虧損主要是由於營業費用的下降,從 7,405 美元降至 1,186 美元,這是由於研發成本、管理持續股票計劃支出和銷售、一般和行政支出的降低推動的。非營業性支出由於利息費用增加而略有增加。公司還認定了一項 656 美元的股票期權的視爲股息。FOXO 科技公司繼續專注於商業化表觀遺傳標誌物科技,暫停銷售新的壽險產品以保護現金。公司的流動性地位仍然令人關注,截至 2024 年 3 月 31 日,現金及現金等價物爲 3 美元,並正在努力獲得額外資金支持。公司未來的計劃包括追求戰略收購,例如提議收購 Rennova 社區健康公司,該收購預計將提供正面的營業性現金流,但無法保證交易完成或成功。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息